ESMO 2024 GU Update

Today’s episode is focusing on what you need to know regarding myelodysplastic syndrome (MDS). This will include the high yield facts on risk factors, diagnostic work-up, staging and treatment of MDS, we were overdue do this this topic, last done in 2022. 

This week’s episode will be focusing on syndromes of iron overload. We will go over all important details on hemochromatosis and other related diseases. We last covered this topic in 2023. 

This week’s episode will be focusing on how to approach a newly diagnosed malignancy, biopsy, staging, patient considerations ect. 

<p>Matt Galsky describes his ESMO 2024 abstract of disitimab vedotiin + pembrlizumab in bladder cancer</p> 

<p>The UROONCO RCC editorial board chief editor Dr. Carmen Mir, and associate editors Dr. Teele Kuusk and Dr. Riccardo Bertolo share highlights of the important kidney cancer developments for 2024. <br/><br/>They summarise the results on several important trials such as FASTRACK, ... Show More

Stay up-to-date on the latest advancements and treatment strategies in the field of genitourinary oncology. In this episode of BackTable Urology, guest host Dr. Bogdana Schmidt, a urologic oncologist from the University of Utah, discusses takeaways from ASCO 2024 with Dr. Petros ... Show More

<p>Drs. Neeraj Agarwal and Jeanny Aragon-Ching discuss several key abstracts to be presented at the 2024 ASCO GU Cancers Symposium, including sequencing versus upfront combination therapies for mCRPC in the BRCAAway study, updates on the CheckMate-9ER and CheckMate-214 trials in ... Show More

Silke, Tom and Brian discuss the prostate and RCC highlights from ESMO 2025 

What to look out for in bladder, prostate and renal cancer at this year's meeting. 

<p>Drs. Neeraj Agarwal and Todd Morgan discuss CONTACT-02, KEYNOTE-564, CheckMate-67T, and other notable studies featured at the 2024 ASCO Genitourinary Cancers Symposium, as well as additional key abstracts in prostate, kidney, and bladder cancers that will significantly influen ... Show More